Merck & Co Inc (MRK) reports robust oncology growth and strategic acquisitions, despite facing headwinds from generic competition and declining vaccine sales.

On a per-share basis, the Rahway, New Jersey-based company said it had net income of $1.19. Earnings, adjusted for restructuring costs and costs related to mergers and acquisitions, came to $2.04 per ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and ...

A long-standing ask from drugmakers, it was expected to expand such programmes to more patients on the drugs, or for more drugs to be supported by such PAPs. Almost a year on, and a day away from ...

HONG KONG, Jan. 28, 2026 /PRNewswire/ -- (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...

Moderna and Merck's melanoma vaccine, combined with Keytruda, could halve cancer recurrence risk, marking a breakthrough in ...

The Morning Bull - US Market Morning Update Tuesday, Jan, 27 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.2%, as investors weigh stronger ...

This month, Moderna and Merck announced that their experimental melanoma vaccine, combined with the immunotherapy Keytruda, ...